{"commentary":{"count":101,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":40,"podcast":37,"x_thread":24},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02504372\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"PEARLS","nct_id":"NCT02504372","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=pearls-nct02504372. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"PEARLS","arms":[{"description":"Participants receive pembrolizumab 200 mg, intravenously (IV), every 3 weeks, for one year (expected maximum 18 doses).","label":"Pembrolizumab","type":"EXPERIMENTAL"},{"description":"Participants receive placebo, IV, every 3 weeks, for one year (expected maximum 18 doses).","label":"Placebo","type":"PLACEBO_COMPARATOR"}],"collaborators":["ETOP","European Organisation for Research and Treatment of Cancer - EORTC"],"completion_date":{"date":"2026-01-21","type":"ACTUAL"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":1177,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Pembrolizumab","type":"BIOLOGICAL"},{"name":"Placebo","type":"OTHER"}],"last_update":"2026-03-17","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Randomized, Phase 3 Trial With Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) Versus Placebo for Patients With Early Stage NSCLC After Resection and Completion of Standard Adjuvant Therapy (PEARLS)","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2023-01-24","type":"ACTUAL"},"primary_outcomes":[{"measure":"Disease-Free Survival (DFS)","timeFrame":"Up to approximately 84 months"},{"measure":"DFS in Programmed Death Ligand-1 (PDL-1) Strong Positive Participants With Tumor Proportion Score (TPS) ≥50%","timeFrame":"Up to approximately 84 months"}],"references":[{"citation":"O'Brien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L, Esteban E, Isla D, Martinez-Marti A, Faehling M, Tsuboi M, Lee JS, Nakagawa K, Yang J, Samkari A, Keller SM, Mauer M, Jha N, Stahel R, Besse B, Peters S; EORTC-1416-LCG/ETOP 8-15 - PEARLS/KEYNOTE-091 Investigators. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022 Oct;23(10):1274-1286. doi: 10.1016/S1470-2045(22)00518-6. Epub 2022 Sep 12.","pmid":"36108662","type":"DERIVED"}],"start_date":{"date":"2015-11-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)","url":"https://clinicaltrials.gov/study/NCT02504372"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/pearls-nct02504372"}